Floatz logo

RELEBACTAM

Pneumonia, Bacterial

Hartford HospitalSmall moleculePhase 4 / ApprovedActive
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Pneumonia, Bacterial cohort.

Asset / SponsorPhaseRating
Cefiderocol
Hartford Hospital
Phase 4BB
IMIPENEM
Hartford Hospital
Phase 4BB
CILASTATIN
Hartford Hospital
Phase 4B

Same molecule, other indications

RELEBACTAM is also rated in:

Critical IllnessDormant
CCC
Indicative ·
53 / 100
View asset →
cystic fibrosisDormant
CCC
Indicative ·
52 / 100
View asset →
hematopoietic and lymphoid cell neoplasmDormant
CCC
Indicative ·
48 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →